Bill > SB193

This bill requires health insurance providers in New Mexico to cover at least one injectable glucagon-like peptide-1 (GLP-1) receptor agonist drug for chronic weight management in adults with obesity, across multiple types of health insurance plans including group health coverage, individual and group health insurance policies, health care plans, health maintenance organization (HMO) contracts, and nonprofit health care plans. A GLP-1 receptor agonist is a type of medication originally developed for diabetes treatment that has shown significant effectiveness in weight loss, with popular brand names like Ozempic and Wegovy. The bill mandates that any health insurance policy that provides prescription drug coverage must include coverage for such weight management medications, ensuring broader access to these increasingly popular weight loss drugs. These new requirements will apply to all health insurance policies, plans, and contracts that become effective on or after January 1, 2026, giving insurance providers time to adjust their coverage offerings to comply with the new law.

Budget and Finance

https://www.nmlegis.gov/Legislation/Legislation?chamber=S&legtype=B&legno=193&year=25